Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01222754|
Recruitment Status : Completed
First Posted : October 18, 2010
Last Update Posted : June 10, 2021
- Children who are diagnosed with brain tumors known as high grade gliomas or diffuse intrinsic pontine gliomas are generally treated with radiation therapy and chemotherapy. However, these tumors are very difficult to cure, and the tumor frequently begins to grow again even after treatment or surgery. Researchers are interested in determining whether the anticancer drug lenalidomide, which has been used to treat other aggressive types of cancer, is a safe and effective additional treatment for children who are scheduled to receive radiation therapy to treat high grade gliomas or diffuse intrinsic pontine gliomas.
- To determine the safety and effectiveness of lenalidomide, in conjunction with radiation therapy, as a treatment for children who have been diagnosed with high grade gliomas or diffuse intrinsic pontine gliomas.
- Children and adolescents up to 21 years of age who have been diagnosed with high grade gliomas or diffuse intrinsic pontine gliomas and have not had radiotherapy or chemotherapy.
- Participants will be screened with a medical history, physical examination, blood and urine tests, and imaging studies.
- Participants will have two phases of treatment: a lenalidomide plus radiation phase and a lenalidomide-only phase.
- During the radiation phase, participants will take lenalidomide daily and have 6 weeks of radiation therapy (five treatments per week). After the radiation therapy, participants will stop taking lenalidomide for 2 weeks before continuing to the next phase.
- During the lenalidomide-only phase, participants will take lenalidomide daily for 21 days, followed by 7 days without lenalidomide (28-day cycle of treatment). Participants will have up to 24 cycles of lenalidomide.
- Participants will have frequent blood tests during the first cycle of treatment, and will have imaging studies or other tests as required by the study researchers.
- Treatment will continue until the disease progresses, the participant chooses to leave the study, or the researchers end the study....
|Condition or disease||Intervention/treatment||Phase|
|Diffuse Intrinsic Pontine Glioma Anaplastic Astrocytoma High Grade Glioma||Drug: Lenalidomide Radiation: XRT, 54-59.4 Gy||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas|
|Actual Study Start Date :||November 23, 2010|
|Actual Primary Completion Date :||April 17, 2019|
|Actual Study Completion Date :||April 17, 2019|
Radiation with Lenalidomide
Radiation: XRT, 54-59.4 Gy
Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
- Tolerability [ Time Frame: 2 years ]The plasma steady state concentration (and CSF levels if available for other reasons) will be correlated with toxicities (type and incidence), time to progression and response.
- Toxicity Profile [ Time Frame: 2 years ]We will also estimate the population parameters using nonlinear mixed effects modeling methods (NONMEM)
- Evaluate MRI Sequences [ Time Frame: 3 years ]
- Progression-free survival [ Time Frame: 4 years ]
- Overall Survival [ Time Frame: 4 years ]
- Biomarkers & toxicity/disease response correlation [ Time Frame: 3 years ]
- Pharmacokinetics correlation with progression and toxicities [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01222754
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||John W Glod, M.D.||National Cancer Institute (NCI)|